Education
About Us
Working with TipRanks
Follow Us
FMED - AI Analysis
Top Page
Fidelity Disruptive Medicine ETF (FMED)
Rating:61Neutral
Price Target:
$28.00
Positive Factors
Strong Top Holdings
Several key holdings, such as Alnylam Pharma and Boston Scientific, have delivered strong year-to-date performance, boosting the ETF's returns.
Focused Sector Exposure
The ETF's heavy allocation to the health care sector provides targeted exposure to a high-growth industry with long-term potential.
Solid Recent Performance
The ETF has shown strong performance over the past three months, indicating positive momentum.
Negative Factors
High Sector Concentration
With over 92% of assets in health care, the fund is highly exposed to risks specific to this sector.
Limited Geographic Diversification
The ETF is heavily weighted toward U.S. companies, offering minimal exposure to international markets.
Moderate Expense Ratio
The fund's expense ratio is higher than some low-cost ETFs, which could slightly reduce investor returns over time.
FMED vs. SPDR S&P 500 ETF (SPY)
AUM59.67M
RegionGlobal
Expense Ratio0.50%
Beta0.86
IssuerFidelity
Inception DateJun 12, 2023
Dividend Yield0.43%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume5,559
30 Day Avg. Volume4,279
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
34.26Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering69
FMED Summary
The Fidelity Disruptive Medicine ETF (FMED) is an investment fund focused on companies driving innovation in healthcare, such as biotechnology, genomics, and digital health. It includes well-known firms like Boston Scientific and Danaher, which are involved in cutting-edge medical technologies and treatments. This ETF is a great option for investors who want to support advancements in healthcare while aiming for long-term growth potential. However, new investors should be aware that the fund is heavily focused on the healthcare sector, meaning its performance could be impacted by changes in the industry or regulatory challenges.
How much will it cost me?The Fidelity Disruptive Medicine ETF (FMED) has an expense ratio of 0.50%, which means you’ll pay $5 per year for every $1,000 invested. This is higher than average because the fund is actively managed, focusing on innovative healthcare companies that require more research and expertise to select.
What would affect this ETF?The Fidelity Disruptive Medicine ETF (FMED) could benefit from ongoing advancements in biotechnology, genomics, and digital health, as well as increased global demand for innovative healthcare solutions. However, it may face challenges from regulatory changes, high research and development costs, and potential market volatility in the healthcare sector. Its global exposure and focus on disruptive medicine make it sensitive to both breakthroughs and setbacks in medical innovation.
FMED Top 10 Holdings
The Fidelity Disruptive Medicine ETF (FMED) is heavily concentrated in the healthcare sector, with a focus on innovative companies driving advancements in biotechnology, genomics, and precision medicine. Argenx is a standout performer, benefiting from strong revenue growth and promising pipeline developments, while Exact Sciences is rising steadily on bullish momentum and positive growth guidance. On the flip side, Insulet and Waystar are showing mixed signals, with valuation concerns and uneven technical trends holding them back. With a global mix of holdings, FMED is a bet on the future of healthcare innovation.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Boston Scientific | 4.85% | $2.87M | $148.62B | 19.42% | 79 Outperform | |
| Alnylam Pharma | 4.82% | $2.86M | $63.13B | 71.09% | 60 Neutral | |
| Argenx Se | 4.31% | $2.55M | $51.24B | 48.98% | 76 Outperform | |
| ― | 3.55% | $2.10M | ― | ― | ― | |
| Danaher | 3.43% | $2.03M | $151.17B | -11.68% | 75 Outperform | |
| Veeva Systems | 3.38% | $2.00M | $46.99B | 33.50% | 77 Outperform | |
| Exact Sciences | 3.36% | $1.99M | $11.88B | -10.96% | 63 Neutral | |
| Insulet | 3.34% | $1.98M | $22.26B | 37.12% | 71 Outperform | |
| Waystar Holding Corp. | 3.02% | $1.79M | $6.90B | 38.68% | 71 Outperform | |
| Intuitive Surgical | 3.00% | $1.77M | $190.57B | 4.64% | 78 Outperform |
FMED Technical Analysis
Positive
―
Price Trends
25.19
Positive
24.49
Positive
24.39
Positive
Market Momentum
0.43
Negative
61.29
Neutral
72.77
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FMED, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 26.07, equal to the 50-day MA of 25.19, and equal to the 200-day MA of 24.39, indicating a bullish trend. The MACD of 0.43 indicates Negative momentum. The RSI at 61.29 is Neutral, neither overbought nor oversold. The STOCH value of 72.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FMED.
FMED Peer Comparison
Comparison Results
Performance Comparison
FMED
Fidelity Disruptive Medicine ETF
26.36
0.78
3.05%
MEDI
Harbor Health Care ETF
―
―
―
MEDX
Horizon Kinetics Medical ETF
―
―
―
TMED
T. Rowe Price Health Care ETF
―
―
―
JDOC
JPMorgan Healthcare Leaders ETF
―
―
―
BMED
Future Health ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents